News

Hosted on MSN3d
Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary
Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase ...
KDFW3d
Zepbound vs. Wegovy: Here's which weight loss drug worked best in first trial
People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s ...
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge
Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...
This Drug Is Nearly 50 Percent More Effective Than Wegovy
A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...
Zepbound Patients Fear Losing Coverage After CVS Deal for Wegovy
Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...
TipRanks on MSN5d
Eli Lilly’s Stock Dips Amid Earnings Outlook Cut
Eli Lilly & Co has experienced a significant stock price drop of 10.58% over the past week, despite delivering impressive first-quarter results for 2025. The company’s revenue s ...